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Medium-Term Complications Associated 
With Coronary Artery Aneurysms After 
Kawasaki Disease: A Study From the 
International Kawasaki Disease Registry
Brian W. McCrindle , MD, MPH;  Cedric Manlhiot, PhD;  Jane W. Newburger , MD, MPH;   
Ashraf S. Harahsheh, MD;  Therese M. Giglia, MD;  Frederic Dallaire, MD, PhD;  Kevin Friedman, MD;   
Tisiana Low, MD;  Kyle Runeckles, MSc;  Mathew Mathew, MSc;  Andrew S. Mackie, MD, MS;  Nadine F. Choueiter, MD;  
Pei-Ni Jone, MD;  Shelby Kutty, MD, PhD;  Anji T. Yetman, MD;  Geetha Raghuveer, MD;  Elfriede Pahl, MD;  
Kambiz Norozi, MD, PhD;  Kimberly E. McHugh, MD;  Jennifer S. Li, MD, MHS;  Sarah D. De Ferranti, MD, MPH; 
Nagib Dahdah, MD;  for the International Kawasaki Disease Registry*                                      
BACKGROUND: Coronary artery aneurysms (CAAs) may occur after Kawasaki disease (KD) and lead to important morbidity 
and mortality. As CAA in patients with KD are rare and heterogeneous lesions, prognostication and risk stratification are 
difficult. We sought to derive the cumulative risk and associated factors for cardiovascular complications in patients with 
CAAs after KD.
METHODS AND RESULTS: A 34-institution international registry of 1651 patients with KD who had CAAs (maximum CAA Z 
score ≥2.5) was used. Time-to-event analyses were performed using the Kaplan–Meier method and Cox proportional 
hazard models for risk factor analysis. In patients with CAA Z scores ≥10, the cumulative incidence of luminal narrowing 
(>50% of lumen diameter), coronary artery thrombosis, and composite major adverse cardiovascular complications at 
10 years was 20±3%, 18±2%, and 14±2%, respectively. No complications were observed in patients with a CAA Z score 
<10. Higher CAA Z score and a greater number of coronary artery branches affected were associated with increased risk 
of all types of complications. At 10 years, normalization of luminal diameter was noted in 99±4% of patients with small 
(2.5≤Z<5.0), 92±1% with medium (5.0≤Z<10), and 57±3% with large CAAs (Z≥10). CAAs in the left anterior descending and 
circumflex coronary artery branches were more likely to normalize. Risk factor analysis of coronary artery branch level out-
comes was performed with a total of 893 affected branches with Z score ≥10 in 440 patients. In multivariable regression 
models, hazards of luminal narrowing and thrombosis were higher for patients with CAAs of the right coronary artery and 
left anterior descending branches, those with CAAs that had complex architecture (other than isolated aneurysms), and 
those with CAAs with Z scores ≥20.
CONCLUSIONS: For patients with CAA after KD, medium-term risk of complications is confined to those with maximum CAA Z 
scores ≥10. Further risk stratification and close follow-up, including advanced imaging, in patients with large CAAs is warranted.
Key Words: cardiovascular outcomes ■ coronary artery ■ Kawasaki disease ■ risk factors
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Kawasaki disease (KD) is a pediatric systemic vas-culitis with a predilection for the coronary arteries. Coronary artery aneurysms (CAAs) are recognized 
as the most important complication of KD, leading to 
significant morbidity and mortality. As a result, KD is 
now thought to be the leading cause of acquired heart 
disease in children of developed countries.1,2 Despite 
optimal acute management, CAAs still develop in ≈4% 
of cases. The prevalence of CAAs increases to 25% if 
the diagnosis of KD is missed or treatment is delayed.1 
Thrombosis in large CAAs can lead to total occlusion 
and myocardial infarction (MI) and sudden death.1 In 
the long-term, CAAs accompanied by chronic inflam-
mation and luminal myofibroblastic proliferation have 
the potential to reduce the size of CAA, but the process 
may eventually cause luminal narrowing. Additionally, 
nonocclusive organized thrombus and recanalized oc-
clusive thrombus can contribute to luminal narrowing.1 
An angiographic study published in 1986 found that 
there was low prevalence of occlusion and stenosis 
early on after the acute KD period, and that compli-
cations often occurred at least 1  year from disease 
onset.3 These findings were later supported by a large 
historical Japanese cohort reported by Kato et al.4 This 
highlights the importance of uninterrupted long-term 
follow-up with serial imaging to determine the risks of 
cardiac complications in patients with KD and inform 
tailored management strategies.
Given the heterogeneity of patients with CAAs and 
their rarity at any single institution, there are a paucity of 
data available to inform more precise risk stratification 
for outcomes in this population. In addition, a limited 
number of risk factors have been identified for adverse 
outcomes, which has impeded the development and 
evaluation of long-term surveillance and management 
strategies calibrated to individual risk. Therefore, we 
sought to determine the cumulative risk and associ-
ated factors for adverse cardiovascular outcomes for 
patients with KD and CAAs using data from the IKDR 
(International Kawasaki Disease Registry), a large, cu-
rated, multi-institutional registry including medium- to 
long-term clinical follow-up.
METHODS
Because of the sensitive nature of the data collected 
for this study, requests to access the data set from 
qualified researchers trained in human subject confi-
dentiality protocols may be sent to the research ethics 
board of The Hospital for Sick Children at researcheth-
ics.board2@sickkids.ca and to the corresponding au-
thor of this study to initiate the process. Authorization 
from all institutions who participated in this study will 
be required to access the data set.
Study Population
Data for this study was collected by the IKDR, which 
included 34 pediatric referral centers in Canada, the 
CLINICAL PERSPECTIVE
What Is New?
• Medium-term cardiac complications of coro-
nary artery aneurysms secondary to Kawasaki 
disease are relatively frequent but generally lim-
ited to patients with maximum coronary artery Z 
scores >10.
• While patients with coronary artery Z scores 
>10 were previously thought to represent a 
common risk category, increased risk profile 
was observed for patients with coronary artery 
Z scores >20.
• Physical properties of coronary artery aneu-
rysms are associated with the risk of complica-
tions potentially by affecting blood rheology.
What Are the Clinical Implications?
• While still requiring ongoing follow-up, patients 
with small or medium coronary artery aneu-
rysms can likely be managed with low-intensity, 
antiplatelet-based thromboprophylaxis and are 
unlikely to need anticoagulation.
• Given the substantial risk of complications, 
combined thromboprophylaxis with both an-
ticoagulation and antiplatelet agents should 
be considered in patients with giant coronary 
artery aneurysms, particularly those with coro-
nary artery Z scores >20.
Nonstandard Abbreviations and Acronyms
AHA American Heart Association
CAA coronary artery aneurysm
CI cumulative incidence





LAD  left anterior descending coronary 
artery
LCX left circumflex artery
LMCA left main coronary artery
MI myocardial infarction
RCA right coronary artery
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United States, and Taiwan. To be eligible for the reg-
istry, patients younger than 18 years must have been 
diagnosed with complete or incomplete KD between 
1999 and 2017 and have at least 1 CAA with a maxi-
mum coronary artery Z score ≥2.5 at any time after 
diagnosis based on the American Heart Association 
(AHA) recommendations for risk stratification.1 Patients 
seen at participating centers only for a single consulta-
tion (or in the acute phase only) and patients seen for 
the first time at the reporting center >3 months after 
the acute phase were not eligible for the registry. For 
the purpose of this study, data harvest was performed 
on March 1, 2018, and included all follow-up informa-
tion up to December 31, 2017. Participating centers 
were required to submit all cases that met all inclusion 
criteria and none of the exclusion criteria, thus prevent-
ing potential selection bias.
Data Acquisition
Data were retrospectively collected by participat-
ing centers and entered using centralized Research 
Electronic Data Capture (REDCap) tools, which is a 
secure, web-based application designed to support 
data capture for research studies, hosted at SickKids 
Hospital (Toronto, Canada).5 Personnel from the data 
coordinating center (also hosted at SickKids Hospital) 
reviewed patient data for eligibility and performed data 
validation and verification. Participation in the IKDR 
requires institutional review board or research ethics 
board approval for the study at the US and Canadian/
Taiwanese sites, respectively, with the institutional re-
view board/research ethics board approving a waiver 
of consent for the collection of retrospective data. 
SickKids Hospital was responsible for managing all bi-
lateral data sharing agreements.
Data Collection
The IKDR collects deidentified information regarding 
patient demographics, details of hospitalization for 
the acute KD episode, short- and long-term manage-
ment, imaging data, and complications. As per AHA 
guidelines, patients with prolonged fever but ≤3 of the 
classic clinical features of KD were classified as having 
incomplete KD. Copies of all imaging reports (echocar-
diograms, angiograms, computed tomography scans, 
and magnetic resonance imaging) were submitted to 
the data coordinating center for centralized data ex-
traction, and the coronary arteries of all patients were 
characterized and classified. Serial absolute internal lu-
minal diameters were retrieved from echocardiography 
reports, and the measurements were adjusted for body 
surface area (recalculated using the Haycock formula 
for all patients to ensure consistency) by calculation 
of Z scores using the Boston coronary artery Z score 
equations (the left anterior descending artery [LAD] 
equation was used for the left circumflex artery [LCX]).2 
Based on maximal Z score, CAAs were classified as 
small (2.5≤Z<5), medium (5≤Z<10), and large (Z≥10), as 
per 2017 AHA guidelines.1 Data extracted from writ-
ten reports of imaging study included the number of 
coronary artery branches with CAAs and the maxi-
mum CAA Z score ever reached. The coronary artery 
architecture was classified as dilatation only, isolated 
CAA in an otherwise normal vessel, isolated CAA in a 
dilated vessel, or complex CAAs. Complex CAA was 
defined as any coronary artery branch with >1 discrete 
lesion or with CAAs extending into the bifurcation of 
the left main coronary artery. The CAA location within 
the branch, the CAA shape and length of the CAA 
when reported, the CAA diameter to length ratio, and 
the estimated CAA ellipsoid area (diameter multiplied 
by length×0.80) were also assessed. Normalization of 
CAA diameter was defined as the reduction of the in-
ternal diameter of a CAA during follow-up to achieve a 
Z score <2.5.
Patient Outcomes
Complications of CAAs were defined as: (1) luminal 
narrowing clinically reported as significant coronary 
artery stenosis/obstruction confirmed on coronary ar-
tery angiography (>50% narrowing of lumen diameter); 
(2) coronary artery revascularization either by cath-
eterization or surgery; (3) coronary artery thrombosis 
(occlusive or nonocclusive) diagnosed on any imag-
ing modality; (4) MI reported clinically; and (5) major 
adverse cardiac complications, including a compos-
ite of surgical or catheter-based revascularization, MI, 
cardiac ischemia, heart transplantation, or death from 
cardiac causes.
Statistical Analysis
Data are presented as means with SDs, medians with 
interquartile ranges (IQRs), and frequencies as ap-
propriate. Time-related freedom from outcomes was 
calculated using the Kaplan–Meier method (presented 
as cumulative incidence rate rather than freedom from 
event). Patient follow-up intervals were censored at last 
follow-up or death. Multivariable risk factor analysis 
was performed using Cox proportional hazard analy-
sis, with variable selection informed using bootstrap 
resampling (500 random samples, P<0.05 to enter 
and P<0.10 to remain).6 Variables with high reliability 
(ie, selected in >50% of the random samples) were 
then included in a multivariable Cox proportional haz-
ard model. Backward selection of variables was then 
used to obtain a final model. Proportional hazard as-
sumption was tested by assessing the statistical sig-
nificance of the time-dependent covariate (interaction 
between the time component and each parameters) in 
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a violation of the proportional hazard assumption. A 
complete list of variables considered in the risk factor 
analysis can be found in Table 1. Note that acetylsali-
cylic acid use was not included in risk factor analysis 
given that >99% of patients were taking this medica-
tion, and long-term treatments (eg, antithrombotics, 
β-blockers, and statins) were not included given their 
time-varying nature. Pertinent negatives are reported. 
For the analysis by affected coronary artery branch, 
only branches with CAA maximal Z score ≥10 were in-
cluded. While each branch is unique, patients could 
have had >1 branch with CAA Z score ≥10. For this 
analysis, adjustment for repeated measures (multi-
ple branches included from the same patient) was 
performed by including the model-based estimate 
for the covariance matrix as a regression term in the 
Cox proportional hazard model. Kaplan–Meier analy-
ses were performed for up to 10 years postdiagnosis, 
after which the number of patients remaining at risk 
was deemed too low to generate valid estimates. All 
statistical analyses were performed using SAS version 
9.4 (SAS Institute Inc).
RESULTS
Patient and CAA Characteristics
A total of 1651 patients were included in this analysis, 
of whom 1184 (72%) were men, as expected given the 
sex distribution of KD. The median age at diagnosis 
was 2  years (IQR, 0.67–4.67  years; range 1  month–
17.9  years), with 744 (45%) aged between 1 and 
5 years. Patients had a median fever duration of 9 days 
(IQR, 7–13 days), and 973 of 1633 (60%) had complete 
KD. Maximum Z scores of any of the 4 coronary artery 
branches (right coronary artery [RCA], left main coro-
nary artery [LMCA], LAD, or LCX) were used to catego-
rize patients as having small 854 (52%), medium 357 
(22%), and large 440 (27%) CAAs. Notably, a greater 
degree of coronary artery complications was associ-
ated with extremes of the age spectrum (younger and 
older), having incomplete rather than complete KD, 
longer duration of fever before treatment, nonresponse 
to first treatment with intravenous immunoglobulins 
(IVIGs) as indicated by need for immunosuppressive 
therapy beyond the initial IVIG cycle, and longer total 
duration of fever. Complete patient characteristics 
stratified by degree of coronary artery involvement are 
presented in Table 2.
Complications of CAAs
Median duration of follow-up was 2.1 years (IQR, 0.9–
6.4; 5th–95th percentile: 0.1–12.5) (total of 6366 pa-
tient-years of follow-up) for all patients. Follow-up was 
substantially longer for patients with large CAAs, with a 
median of 5.2 years (IQR, 1.9–8.9; 5th–95th percentile: 
0.3–14.3) (P<0.001). No complications were reported 
for patients with small CAAs. Only 1 patient with a me-
dium CAA (maximum Z score of 8.5) experienced a 
cardiac complication (chronic cardiac ischemia result-
ing in heart failure and death); this patient happened to 
have CAAs in all 4 coronary artery branches. Figure 1 
presents the cumulative incidence (CI) of 6 major 
complications in patients with large CAAs, including 
luminal narrowing (10-year CI, 20±3%), coronary ar-
tery interventions (10-year CI, 10±2%), coronary artery 
thrombosis (10-year CI, 18±2%), MI (10-year CI, 5±2%), 
composite major adverse cardiac complications (10-
year CI, 14±2%), and death from cardiac causes or 
heart transplantation (10-year CI, 2±1%).
Table 1. Patients and CAA Characteristics Considered 





Type of KD (complete/incomplete)
Arthritis at diagnosis








Red blood cell count, ×1012/L
Aspartate transaminase, U/L
Alanine aminotransferase, U/L
Duration of fever before IVIGs
Total duration of fever
IVIG treatment
No. of IVIG doses
Intravenous steroids in the acute phase
Oral steroids in the acute phase
Infliximab in the acute phase
Any use of nonsteroidal anti-inflammatory drugs in the acute phase
Coronary artery branch
Maximum coronary artery Z score
Involvement of the LAD/LMCA/LCX bifurcation
Aneurysm architecture
Aneurysm location within coronary branch
Aneurysm shape
Aneurysm width to height ratio
Aneurysm estimated area
CAA indicates coronary artery aneurysm; ESR, erythrocyte sedimentation 
rate; IVIG, intravenous immunoglobulin; KD, Kawasaki disease; LAD, left 
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Table 2. Patient Characteristics Stratified by Maximum Degree of Coronary Artery Involvement
No. All Patients No. Small CAA No. Medium CAA No. Large CAA P Value
Acute phase presentation
Men 1651 1184 (72%) 854 623 (73%) 357 245 (69%) 440 316 (72%) 0.32
Age at diagnosis, y 1651 2.0 (0.7–4.7) 854 2.4 (1.1–5.0) 357 1.5 (0.5–3.8) 440 1.4 (0.4–4.7) <0.001
Age at diagnosis category, y 1651 854 357 440 <0.001
<0.5 282 (17%) 78 (9%) 76 (21%) 128 (29%)
0.5 to <1 240 (15%) 113 (13%) 61 (17%) 66 (15%)
1 to <5 744 (45%) 447 (52%) 155 (43%) 142 (32%)
5 to <10 306 (19%) 171 (20%) 56 (16%) 79 (18%)
≥10 79 (5%) 45 (5%) 9 (3%) 25 (6%)
Any acute readmission 1508 223 (15%) 757 79 (10%) 331 44 (13%) 420 100 (23%) <0.001
Fever pre-IVIGs, d 1578 7 (5–10) 824 6 (5–8) 348 7 (5–10) 406 9 (6–14) <0.001
Fever post-IVIGs, d 1527 1 (0–3) 783 1 (0–2) 344 1 (0–3) 400 1 (0–5) <0.001
Total fever duration, d 1553 9 (7–13) 798 8 (6–10) 348 9 (7–12) 407 13 (9–17) <0.001
Length of hospital stay, d 1576 5 (3–8) 802 4 (3–6) 352 5 (3–9) 422 8 (4–15) <0.001
Conjunctivitis 1616 1462 (91%) 835 756 (91%) 354 317 (90%) 427 389 (91%) 0.75
Cervical lymphadenopathy 1616 653 (40%) 835 367 (44%) 354 130 (37%) 427 156 (37%) 0.01
Rash 1618 1386 (86%) 837 717 (86%) 354 315 (89%) 427 354 (83%) 0.05
Erythema/edema of extremities 1593 978 (61%) 823 527 (64%) 348 206 (59%) 422 245 (58%) 0.08
Mucosal changes 1616 1237 (77%) 835 677 (81%) 354 256 (72%) 427 304 (71%) <0.001
No. of KD symptoms 1597 828 351 418 0.006
1 56 (3%) 26 (3%) 12 (3%) 18 (4%)
2 175 (11%) 71 (8%) 48 (13%) 56 (13%)
3 436 (26%) 208 (24%) 101 (28%) 127 (29%)
4 648 (39%) 363 (43%) 137 (38%) 148 (34%)
5 282 (17%) 160 (19%) 53 (15%) 69 (16%)
Type of KD reported 1633 845 355 433 <0.001
Complete 973 (60%) 549 (65%) 199 (56%) 225 (52%)
Incomplete 660 (40%) 296 (35%) 156 (44%) 208 (48%)
Arthritis 1384 170 (12%) 718 87 (12%) 310 24 (8%) 356 59 (17%) 0.002
Weight before first IVIG dose, kg 1401 13 (9–19) 700 13 (10–19) 309 12 (8–17) 392 11 (8–20) <0.001
Duration of follow-up, y 1651 2.1 (0.9–6.4) 854 1.2 (0.4–3.4) 357 2.8 (1.0–6.3) 440 5.2 (1.9–8.9) <0.001
Laboratory values at admission
Hemoglobin, g/L 1350 105.7±14.2 732 108.6±12.8 295 103.6±14.2 323 101.2±15.7 <0.001
Hematocrit, % 1300 0.31±0.04 716 0.32±0.04 282 0.31±0.04 302 0.30±0.04 <0.001
Red blood cell count, ×1012/L 1042 4.0 (3.6–4.3) 526 4.1 (3.8–4.4) 246 3.9 (3.6–4.3) 270 3.8 (3.4–4.2) <0.001
White blood cell count, ×109/L 1358 16.1±6.8 729 14.9±5.7 303 16.6±6.7 326 18.2±8.4 <0.001
Platelets, ×109/L 1339 442±220 719 395±170 295 467±242 325 523±265 <0.001
ESR, mm/h 1166 62 (46–88) 647 60 (45–85) 257 61 (46–85) 262 70 (50–100) <0.001
C-reactive protein, mg/L 1140 20 (9–84) 629 18 (8– 69) 246 20 (8–96) 265 25 (12–106) 0.004
Albumin, g/L 1003 31.6±6.4 553 33.1±6.2 222 30.8±6.1 228 28.8±6.2 <0.001
Aspartate transaminase, U/L 946 36 (25–58) 494 37 (27–61) 220 34 (24–55) 232 33 (24–53) 0.02
Alanine aminotransferase, U/L 1202 35 (19–74) 684 38 (20–90) 259 33 (18–64) 259 32 (19–57) 0.04
Acute treatment
At least 1 IVIG course 1646 1592 (97%) 852 828 (97%) 357 350 (98%) 437 414 (95%) 0.03
No. of IVIG doses 1643 852 357 434 <0.001
0 54 (3%) 24 (3%) 7 (2%) 23 (5%)
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There were 8 deaths overall: 1 with medium and 7 with 
large CAAs. The 1 patient with medium CAAs in all 
4 branches (mentioned above) died of chronic isch-
emia 6  months after the acute phase. Four deaths 
were secondary to MI (3 within 6 weeks of the acute 
phase and 1 that occurred 18 months after the acute 
phase). The other 3 patients died of noncardiac causes 
(1 mitochondrial disorder and 2 trauma). In addition, 2 
patients with large CAAs underwent heart transplanta-
tion at 5 months and 4 years after the acute phase. A 
higher maximum CAA Z score and higher number of 
coronary artery branches affected were strongly asso-
ciated with the composite outcome of major cardiac 
complications (Table 3).
Branch Level Outcomes
Given that the risk of complications was associated 
with specific CAA characteristics (as opposed to 
being determined solely at the patient level), risk fac-
tor analyses were performed at the coronary artery 
branch level for branches with at least 1 CAA with a Z 
score ≥10. CAAs with Z scores <10 were not included 
in this analysis because of our finding that there was 
no substantial risk of complications in those patients. 
A total of 893 CAAs in 440 patients were included in 
this analysis, with 370 (42%) in the LAD, 297 (33%) in 
the RCA, 135 (15%) in the LCX, and 91 (10%) in the 
LMCA. The majority (603, 68%) of branches included 
had maximum CAA Z scores 10 to 19.9, 195 (22%) had 
Z scores 20 to 29.9, 48 (5%) had Z scores 30 to 39.9 
(5%), and 47 (5%) had Z scores ≥40. Complete details 
of the architecture of CAAs by branch are presented in 
Table 4. This analysis focused on 3 branch-level out-
comes: narrowing of luminal diameter >50% of normal, 
coronary artery thrombosis, and normalization of lumi-
nal diameter. Given that vascular interventions and MIs 
may be a consequence of the first 2 categories, risk 
factors are presumed likely to be the same. Vascular 
interventions and MIs were not analyzed as separate 
outcomes.
At 10 years, luminal narrowing affected 12±1% of 
all branches with large CAAs, with substantially higher 
rates of narrowing for CAAs in the RCA and the LAD 
(versus LMCA and LCX) and in branches with CAAs 
with Z scores ≥20 (Figure 2). The complete list of fac-
tors associated with luminal narrowing in multivariable 
Cox regression models is provided in Table 5. Other 
than CAA branch and higher CAA size, complex CAA 
architecture was also associated with greater haz-
ard of luminal narrowing. Some characteristics of the 
acute phase were also associated with an increased 
hazard of luminal narrowing, namely lower number of 
IVIG doses (ie, cycles) during the acute phase, lower 
serum albumin levels, and higher total number of days 
of fever before treatment with IVIGs.
Thrombosis affected 11±1% of all branches with 
large CAAs by 10 years, with a predilection for the RCA 
and the LAD, and for branches with CAAs with Z score 
≥20 (Figure 2). The complete list of factors associated 
with coronary artery thrombosis in multivariable Cox 
regression models is provided in Table 6. Factors as-
sociated with an increased risk of thrombosis included 
greater maximum CAA Z score, no treatment with 
IVIGs in the acute phase, complex CAA architecture, 
and lower serum C-reactive protein in the acute phase.
Normalization of luminal diameter at 10  years oc-
curred in 57±3% of branches with large CAAs, which 
was substantially lower than the rate of normalization for 
branches with medium (92±1%) or small CAAs (99±4%) 
(Figure 3). Large CAAs in the LAD and LCX were more 
likely to normalize in dimensions compared with those 
in the RCA or LMCA, and the hazard of normalization 
was inversely proportional to the maximum Z score 
of the CAA (Figure 2). The complete list of factors as-
sociated with normalization of luminal diameter in the 
multivariable regression model are shown in Table 7. 
Other than coronary artery branch and the maximum 
size of the CAA, factors associated with increased risk 
of normalization were lower total CAA ellipsoid area, 
treatment with IVIGs in the acute phase, female sex, 
No. All Patients No. Small CAA No. Medium CAA No. Large CAA P Value
2 506 (31%) 214 (25%) 125 (35%) 167 (38%)
3 66 (4%) 14 (2%) 16 (5%) 36 (8%)
≥4 8 (1%) 0 (0%) 2 (1%) 6 (1%)
Infliximab 1642 214 (13%) 851 86 (10%) 355 51 (14%) 436 77 (18%) <0.001
Pentoxifylline 1591 7 (0.4%) 816 0 (0%) 346 2 (1%) 429 5 (1%) 0.01
Immunotherapy 1591 46 (3%) 816 10 (1%) 346 11 (3%) 429 25 (6%) <0.001
Any steroids 1594 342 (21%) 817 104 (13%) 348 73 (21%) 429 165 (38%) <0.001
Oral steroids 1592 216 (14%) 817 58 (7%) 346 44 (13%) 429 114 (27%) <0.001
Intravenous steroids 1525 288 (19%) 761 85 (11%) 336 62 (19%) 428 141 (33%) <0.001
Small CAA: 2.5 ≤ Z < 5; Medium CAA: 5 ≤ Z < 10; Large CAA: Z ≥ 10.
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younger age at acute KD, incomplete KD, and lower 
initial erythrocyte sedimentation rate.
CAA shape (saccular or fusiform/irregular), location 
in the vessel (distal, extending, or proximal), and width 
to height ratio were not associated with any cardiac 
complications in multivariable models (although some 
associations were statistically significant at the univari-
able level) (data not shown).
DISCUSSION
In this study, we report that the occurrence of lumi-
nal narrowing, coronary artery thrombosis, and major 
adverse cardiac complications were nearly com-
pletely confined to patients with CAAs with Z scores 
≥10. Importantly, in those patients, the risk continued 
to increase over time, highlighting the importance of 
Figure 1. Cumulative incidence calculated using Kaplan–Meier survival analysis of complications for patients with coronary 
artery aneurysms after Kawasaki disease in patients with at least 1 lesion with a coronary artery Z score ≥10.
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long-term and uninterrupted clinical follow-up. The 
highest risks were associated with CAAs in the LAD and 
RCA with maximum Z scores ≥20 and complex CAA 
architecture. Luminal normalization of coronary artery 
dimension was more likely to occur for CAAs in the 
LAD and LCX branches, with the likelihood of normali-
zation inversely related to the initial maximum Z score 
of CAA. Additional factors such as IVIG treatment dur-
ing the acute phase, lower erythrocyte sedimentation 
rate, and lower total CAA area were also associated 
with an increased likelihood of luminal normalization. 
This study has the advantages of being a large, multi-
institutional, international study, which more precisely 
defines the prevalence of CAA-related cardiovascular 
complications, uses longitudinal Z scores, and defines 
associations with coronary artery branch, with over a 
10-year follow-up.
Risk Stratification
Manlhiot et al7 first demonstrated that, regardless of 
absolute dimensions, a CAA Z score ≥10 represented 
the effective lower bound of risk for cardiac complica-
tions in the medium term after KD. However, we found 
that within groups with large CAAs (Z scores ≥10), the 
risk profile of large aneurysms with Z scores <20 differs 
significantly from aneurysms with Z scores ≥20, with 
the latter being at substantially higher risk of complica-
tions. This is a novel finding that may have important 
implications in the surveillance and management of pa-
tients with CAA Z scores ≥20. We, therefore, propose 
that patients with CAAs that have Z scores ≥20 be fur-
ther distinguished and be regarded as a separate and 
higher risk category than those with CAAs that have 
Z scores between ≥10 and <20. The change in risk 
stratification has important implications for the intensity 
and type of thromboprophylaxis that should be used in 
those patients. In small (2.5≤Z<5) to medium (5≤Z≤10) 
CAAs, where platelet activation is a key factor in initiat-
ing thrombus formation, antiplatelet therapy is likely to 
be effective and is currently the mainstay of therapy. 
However, more aggressive thromboprophylactic ther-
apy with the addition of an anticoagulant is necessary 
in patients with large (Z score ≥10, and even more so 
in those with Z score ≥20) or progressive CAAs, where 
the low shear stress environment and flow stasis leads 
to activation of the clotting cascade.8
The 2017 AHA guidelines considered omitting 
echocardiographic evaluation in children with small 
Table 3. Univariable Factors Associated With Composite 
Risk Major Adverse Cardiac Complications in Cox 
Proportional Hazard Analysis for All Patients With KD and 






95% CI P Value
Maximum CAA Z score
≥2.5 to <10 0.19 0.09 0.42 <0.001
≥10 to <20 Reference
≥20 to <30 2.33 1.01 5.40 0.05
≥30 7.63 3.12 18.7 <0.001
No. of CAAs with Z score ≥10
1 0.05 0.02 0.16 <0.001
2 Reference
3 1.98 0.91 4.33 0.09
4 3.13 1.38 7.11 0.006
CAA indicates coronary artery aneurysm; HR, hazard ratio; KD, Kawasaki 
disease.
Table 4. Characteristics of Coronary Artery Branches 

















Isolated aneurysm in normal vessel 161 (18%)
Isolated aneurysm in a dilated vessel 332 (37%)
Complex aneurysms* 251 (28%)
Undefined/unreported 149 (17%)
Aneurysm location within branch
Proximal segment 343 (38%)
Distal segment 79 (9%)






Aneurysm diameter to height ratio (n=312) Median (IQR) 0.73 
(0.53–1.06)
Aneurysm estimated area (n=312) Median (IQR) 0.72 
(0.44–1.34)
IQR indicates interquartile range; LAD, left anterior descending artery; 
LCX, left circumflex artery; LMCA, left main coronary artery; and RCA, right 
coronary artery.
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Figure 2. Cumulative incidence of luminal narrowing, coronary artery thrombosis, and normalization of luminal 
diameter, calculated using Kaplan–Meier survival analysis, for coronary artery aneurysms after Kawasaki 
disease in coronary artery branches with coronary artery Z score ≥10 stratified by coronary artery branches.
LAD indicates left anterior descending coronary artery; LCX, left circumflex artery; LMCA, left main coronary artery; RCA, 
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aneurysms who had normalization of the dimension of 
their coronary artery lumen (risk level 3.2). No patient 
with small CAAs had cardiac complications during the 
follow-up period, and 99% had normalization of their 
CAA luminal diameter. Given our data and a previous 
study by Dionne et al,9 which showed preserved en-
dothelium continuity in patients with small CAAs but 
no actual anatomical aneurysms (ie, dilatation only), 
it would be reasonable to consider discharging these 
patients from cardiology follow-up. This recommenda-
tion is currently only true for children with lower risk 
levels (risk level 1 or 2).1 As cardiologists and when-
ever evidence supports, we ought to empower our pa-
tients to achieve their maximal potential and not leave 
a cloud of being different for those with no evidence of 
complications. Such a label might impact “self-image 
and lifestyle.”10
Examination of Additional Risk Factors
While Manlhiot et al proposed a risk classification 
system based solely on coronary artery Z scores, 
we found evidence that branch-level factors play 
an important role in determining the risk of luminal 
narrowing and thrombosis, as well as the likelihood 
of luminal diameter normalization.7 This supports 
findings from Tsuda et al11 that branch CAAs had a 
higher risk of stenosis compared with bifurcation an-
eurysms. Rheological studies have reported a strong 
negative correlation between shear stress and risk of 
thrombus formation.8,12 In angiographic studies with 
Table 5. Multivariable Factors Associated With Risk Luminal Narrowing Using Cox Proportional Hazard Analysis in 
Branches With CAAs With Z Score ≥10
Multivariable Risk Factors Reliability, % HR Lower 95% CI Upper 95% CI P Value
Maximum CAA Z score 100
≥10 to <20 Reference
≥20 to <30 3.65 1.91 6.98 <0.001
≥30 to <40 4.24 2.00 9.01 <.0001
≥40 7.56 3.19 17.9 <0.001
No. of d of fever before IVIGs 98 1.04 1.01 1.07 0.01
Complex aneurysms architecture 97 1.93 1.24 3.01 0.004
Albumin level, g/L 94 0.92 0.86 0.98 0.008
No. of IVIG cycles 93
0 Reference
1 0.13 0.03 0.54 0.005
2 0.34 0.12 0.96 0.04
3+ 0.48 0.18 1.29 0.15
Branch 78
RCA Reference
LMCA 0.11 0.01 0.82 0.03
LAD 0.58 0.38 0.89 0.01
LCX 0.22 0.07 0.72 0.01
CAA indicates coronary artery aneurysm; HR, hazard ratio; IVIG, intravenous immunoglobulin; LAD, left anterior descending artery; LCX, left circumflex 
artery; LMCA, left main coronary artery; and RCA, right coronary artery.
Table 6. Multivariable Factors Associated With Risk Coronary Artery Thrombosis, Using Cox Proportional Hazard 
Analysis, in Branches With CAAs With Z Score ≥10
Multivariable Risk Factors Reliability, % HR Lower 95% CI Upper 95% CI P Value
Maximum CAA Z score 100
≥10 to <20 Reference
≥20 to <30 3.51 1.84 6.69 <0.001
≥30 to <40 5.74 2.50 13.16 <0.001
≥40 29.5 14.4 60.3 <0.001
Complex aneurysms architecture 88 2.08 1.32 3.26 0.002
Treatment with IVIG 87 0.38 0.19 0.76 0.006
C-reactive protein, 10 mg/L 76 0.95 0.90 0.99 0.02
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Doppler flow, the average peak velocity in the CAA 
was found to decrease as the size of the CAA in-
creased, suggesting that flow stagnation was also a 
risk factor for thrombosis.12–16
In our analysis of CAA architecture, we found that 
both a higher number of CAAs within a coronary 
artery branch, and CAAs of the LAD/LCX involving 
the left bifurcation, increased the risk of complica-
tions in patients with large CAAs. Interestingly, re-
search on atherosclerotic heart disease has found 
that the localization of atherosclerotic lesions to cer-
tain areas within the arterial system, particularly the 
branching sites, could be associated with rheological 
characteristics.14,15
In terms of CAA location, the risk of thrombosis 
and luminal narrowing was higher in CAAs affect-
ing the RCA and LAD coronary artery branches. We 
speculate that this could be a result of several rea-
sons. First, reliability of LMCA measurements has 
been of concern, because of its anatomical varia-
tion.17 Second, being short and high-pressured, the 
walls of the LMCA may be less likely to weaken and 
facilitate sluggish flow. In terms of the LCX branch, 
its distal anatomical placement hinders visualization 
by echocardiography, which creates the possibility 
that stenosis and thrombus development in the area 
were missed.
Taken together, our findings support that these 
additional coronary artery branch–level risk fac-
tors should be taken into account when decisions 
are made regarding risk classification. While we 
Figure 3. Cumulative incidence of normalization of luminal 
diameter, calculated using Kaplan–Meier survival analysis, 
for coronary artery aneurysms (CAAs) after Kawasaki 
disease stratified by level of coronary artery involvement. 
Table 7. Multivariable Factors Associated With Risk of Normalization of Luminal Diameter, Using Cox Proportional Hazard 
Analysis, in Branches With CAAs With Z Score ≥10
Multivariable Risk Factors Reliability, % HR Lower 95% CI Upper 95% CI P Value
Maximum CAA Z score 100
≥10 to <20 Reference
≥20 to <30 0.50 0.38 0.66 0.002
≥30 to <40 0.24 0.12 0.51 <0.001
≥40 0.25 0.10 0.61 <0.001
Aneurysm area, cm2 100
>1.35 7.01 2.38 20.6 <.001
0.71 to 1.35 4.50 1.61 12.6 0.004




LMCA 0.60 0.39 0.91 0.02
LAD 1.94 1.51 2.48 <.001
LCX 2.16 1.55 3.00 <.001
Treatment with IVIGs 94 3.22 1.28 8.13 0.01
Age at acute KD, y 94 0.93 0.89 0.97 0.006
Incomplete KD 85 1.31 0.99 1.73 0.056
ESR, 10 mm/h 78 0.95 0.91 0.99 0.03
Women 67 1.33 1.03 1.72 0.03
CAA indicates coronary artery aneurysm; ESR, erythrocyte sedimentation rate; HR, hazard ratio; IVIG, intravenous immunoglobulin; KD, Kawasaki disease; 
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conclude that CAA architecture was an important 
feature to include for risk stratification, we did not 
find any association between CAA shape (saccular 
versus fusiform) and any of the cardiac complications 
considered in this study, despite this finding being re-
ported in previous studies. This could be associated 
with the fact that almost half of all imaging reports did 
not indicate the shape of the CAAs and, as such, the 
number of missing data were substantial to identify 
a pattern. The development and utilization of better 
methods to characterize CAA lesions would be an 
important next step to further refine risk stratification 
models.
Outcome Comparisons With Previous 
Studies
In a 10- to 21-year follow-up study by Kato et al4 of 146 
patients with KD and CAAs, 90% of patients showed 
normalization of luminal dimensions within the first 
2 years from onset; however, none of the large or giant 
CAAs, defined as having an absolute diameter of at 
least 8  mm, showed normalization of luminal dimen-
sion. A study from the United States by Friedman et 
al18 found an overall CAA proportion of normalization 
of luminal dimensions of 75%, which they believed was 
higher than those reported in previous cohorts attribut-
able to more aggressive treatment. Similar to Kato et al, 
they also found that the probability of normalization of 
luminal dimensions was inversely proportional to CAA 
Z score at diagnosis.18 This was in line with our find-
ings, with >80% of small to medium CAAs and ≈50% of 
large CAAs achieving luminal diameter normalization. 
Friedman et al also reported that major adverse car-
diovascular events occurred exclusively in large CAAs, 
which was similar to our findings, where all complica-
tions occurred in patients with large CAAs, with the ex-
ception of 1 patient with medium CAAs who had CAAs 
in all 4 branches. In our study, the rate of CAA normali-
zation was similar to Friedman et al and larger than Kato 
et al (55%–60%), which speaks to potentially more ag-
gressive management in the current era. However, the 
rate of luminal narrowing for large CAAs with Z score 
≥10 at ≈20% was similar to the data from Kato et al4 
(despite the different definitions of large CAAs), indicat-
ing a need for more aggressive management and/or 
novel approaches in this patient population.
Limitations
This study used echocardiography reports rather 
than an imaging core laboratory; thus, differences 
in methods of measurement by participating cardi-
ologists may have contributed to data variability. A 
secondary analysis of the Pediatric Heart Network’s 
randomized Kawasaki disease trial has previously 
shown moderately good agreement (interclass 
correlation between 0.60 and 0.75 for all segments 
other than the circumflex) between coronary artery 
segment dimensions measured at local centers ver-
sus core laboratory assessment in this context.19 
Regardless of the method of interpretation, echocar-
diography is inferior to advanced imaging modalities 
(eg, computed tomography, magnetic resonance im-
aging, or invasive angiography) in estimating coronary 
artery diameter, particularly the distal coronary artery 
tree, although it is still the standard of care for most 
patients. Not all patients had such advanced imaging 
studies (1% of patients with small CAAs, 5% to 8% of 
patients with medium CAAs, and ≈50% of patients 
with large CAAs divided roughly equally between 
angiography and magnetic resonance imaging). In 
terms of coronary artery branch anatomy, assess-
ment based on reports was required to obtain fea-
tures, which is subject to interpretation error. Another 
source of variation is that outcomes were often de-
tected at the time of imaging rather than when they 
actually occurred, particularly when asymptomatic. 
Last, our study design was retrospective, and there 
was no auditing of data at centers, so we cannot ex-
clude the possibility of selection bias in cases sub-
mitted, although this would be unlikely.
CONCLUSIONS
In this large, multi-institutional international study con-
ducted in patients with KD who had CAAs, we report 
that the risks of luminal narrowing, thrombosis, and 
major adverse cardiovascular complications were 
nearly completely confined to those with maximum 
CAA Z scores ≥10. We can also propose that CAAs 
with Z scores ≥20 should now be considered a sepa-
rate risk strata because of their distinctly greater risk 
profile. The presence of complex CAAs, as well as the 
involvement of LAD and RCA branches, increases an 
individual’s risk for CAA-related complications, and 
these factors should be taken into account on an in-
dividual basis when considering surveillance and man-
agement strategies. Future studies could focus on 
rheology to investigate patient-specific hemodynamic 
factors, which could increase the risk of complica-
tions and assess the effectiveness of more aggressive 
thromboprophylactic regimens, including triple ther-
apy, in patients with CAAs with Z scores ≥20.
APPENDIX
The members of the International Kawasaki Disease 
Registry include: Carolyn A. Altman MD—Texas 
Children’s Hospital, Baylor College of Medicine, 
Houston, TX; Brett R. Anderson MD—Columbia 
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York, NY; Emilie Beaulieu MD—Centre de Recherche 
du Centre Hospitalier Universitaire de Sherbrooke, 
Sherbrooke, Quebec, Canada; Carolyn E. Boychuk 
BSc—Stollery Children’s Hospital, Edmonton, Alberta, 
Canada; Elizabeth Braunlin MD, PhD—University of 
Minnesota, Minneapolis, MN; Jane C. Burns MD—
Department of Pediatrics, University of California 
San Diego, Rady Children’s Hospital-San Diego, 
CA; Michael R. Carr MD—Ann and Robert H. Lurie 
Children’s Hospital of Chicago, IL; Andrew Crean MRCP, 
MPH—Toronto General Hospital, Toronto, Ontario, 
Canada; Jessica H. Colyer MD—Pediatrics Cardiology, 
Children’s National Health System/George Washington 
University, Washington, DC; Adam Dempsey PhD—
Department of Paediatrics, Western University, London, 
Ontario, Canada; Laurent Desjardins MD—Division of 
Pediatric Cardiology, Centre Hospitalier Universitaire 
Ste-Justine, University of Montreal, Quebec, Canada; 
Rejane Dillenburg MD—McMaster Children’s Hospital, 
Hamilton, Ontario, Canada; Audrey Dionne MD—
Division of Pediatric Cardiology, Centre Hospitalier 
Universitaire Ste-Justine, University of Montreal, 
Quebec, Canada; Anna Ferris MBBS—Columbia 
University - College of Physicians and Surgeons, New 
York, NY; Michael Gewitz MD—Maria Fareri Children’s 
Hospital at Westchester Medical Center (WMC) 
Health, New York Medical College, Valhalla, New York; 
Michelle M. Grcic RN, MSN, CNP—The Heart Center at 
Nationwide Children’s Hospital, Columbus, OH; Steven 
C. Greenway MD—Alberta Children’s Hospital, Calgary, 
Alberta, Canada; Kevin C. Harris MD, MHSc—Children’s 
Heart Centre, University of British Columbia, Vancouver, 
British Columbia; Christina Hayden-Rush BSN—The 
Children’s Hospital of Philadelphia, Philadelphia, PA; 
Kevin D. Hill MD—Duke University Medical Center, 
Durham, NC; Supriya Jain MD—Maria Fareri Children’s 
Hospital at Westchester Medical Center (WMC) Health, 
New York Medical College, Valhalla, New York; Thomas 
R. Kimball MD—Heart Institute, Cincinnati Children’s 
Hospital Medical Center, Cincinnati, OH; Sean M. 
Lang MD—Heart Institute, Cincinnati Children’s 
Hospital Medical Center, Cincinnati, OH; Ming-Tai Lin 
MD, PhD—National Taiwan University, Taipei, Taiwan; 
William T. Mahle MD—Children’s Healthcare of Atlanta, 
GA; Tapas Mondal MD—McMaster Children’s Hospital, 
Hamilton, Ontario, Canada; Michael A. Portman MD—
Seattle Children’s Research Institute, Seattle, WA; 
Claudia Renaud MD—Montreal Children’s Hospital, 
McGill University, Montreal, Quebec, Canada; S. 
Kristen Sexson Tejitel MD, PhD, MPH—Texas Children’s 
Hospital, Baylor College of Medicine, Houston, TX; 
Jacqueline R. Szmuszkovicz MD—Children’s Hospital 
of Los Angeles, CA; Karen M. Texter MD—The Heart 
Center at Nationwide Children’s Hospital, Columbus, 
OH; Deepika Thacker MD—Nemours Cardiac Center, 
Nemours/Alfred I. duPont Hospital for Children, 
New Castle County, DE; Elif Seda Selamet Tierney 
MD—Division of Pediatric Cardiology, Department of 
Pediatrics, Stanford University, School of Medicine, Palo 
Alto, CA; Thomas Thomas MD—Pediatric Cardiology, 
Children’s Hospital Colorado, University of Colorado 
School of Medicine, Aurora, CO; Adriana H. Tremoulet 
MS, MAS—Department of Pediatrics, University of 
California San Diego, Rady Children’s Hospital-San 
Diego, CA; Sharon Wagner-Lees RN-BC, BSN, MBA—
Children’s Hospital of Los Angeles, CA; Andrew Warren 
MD—IWK Health Centre, Halifax, Nova Scotia, Canada.
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